China NMPA Drug Inspection - Hubei Ruizhe Pharmaceutical Co., Ltd. - Doxophylline for Injection

China NMPA drug inspection for Hubei Ruizhe Pharmaceutical Co., Ltd. published September 21, 2018. Drug: Doxophylline for Injection.

View on Dashboard

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

China NMPA drug inspection for Hubei Ruizhe Pharmaceutical Co., Ltd. published September 21, 2018. Drug: Doxophylline for Injection.

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Hubei Ruizhe Pharmaceutical Co., Ltd.

Inspection Date

Unknown Date

Product Type

ID: 42643bcc-32be-47e3-b39e-3951c9fe8e92

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox